Interleukin-6/10 Ratio as a Prognostic Marker of Recurrence in Patients With Intermediate Risk Urothelial Bladder Carcinoma

Journal of Urology

Volumn 178, Issue 5, 2007, Pages 1906-1912

  Cai, Tommaso ^a   Mazzoli, Sandra ^b   Meacci, Francesca ^b   Tinacci, Galliano ^b   Nesi, Gabriella ^a   Zini, Enzo ^b   Bartoletti, Riccardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

bladder; bladder neoplasms; interleukin 10; interleukin 6; neoplasm recurrence, local; urothelium

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CONTROLLED STUDY; CYSTECTOMY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; TRANSURETHRAL RESECTION; URINALYSIS; URINE CYTOLOGY;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; URINE;

EID: 35148860968     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.07.041     Document Type: Article

References (20)

1. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C., Denis L., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466
2. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790
3. Snyder C., Harlan L., Knopf K., Potosky A., and Kaplan R. Patterns of care for the treatment of bladder cancer. J Urol 169 (2003) 1697
4. Giannopoulos A., Manousakas T., Gounari A., Constantinides C., Choremi-Papadopoulou H., and Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA Stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 166 (2001) 470
5. Offersen B.V., Knap M.M., Marcussen N., Horsman M.R., Hamilton-Dutoit S., and Overgaard J. Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis. Br J Cancer 87 (2002) 1422
6. Cai T., Nesi G., Boddi V., Mazzoli S., Dal Canto M., and Bartoletti R. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma. Oncol Rep 16 (2006) 329
7. Kim J.H., Shariat S.F., Kim I.Y., Menesses-Diaz A., Tokunaga H., Wheeler T.M., et al. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 1475
8. Watanabe E., Matsuyama H., Matsuda K., Ohmi C., Tei Y., Yoshihiro S., et al. Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette-Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunol Immunother 52 (2003) 481
9. Barton B.E. Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes. Expert Opin Ther Targets 9 (2005) 737
10. Liang B., Gardner D.B., Griswold D.E., Bugelski P.J., and Song X.Y. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 119 (2006) 296
11. Seguchi T., Yokokawa K., Sugao H., Nakano E., Sonoda T., and Okuyama A. Interleukin-6 activity in urine and serum in patients with bladder carcinoma. J Urol 148 (1992) 791
12. Mulé J.J., McIntosh J.K., Jablons D.M., and Rosenberg S.A. Antitumor activity of recombinant interleukin 6 in mice. J Exp Med 171 (1990) 629
13. Sabat R., and Asadullah K. Interleukin-10 in cancer immunity. In: Stuhler G., and Walden P. (Eds). Cancer Immune Therapy: Experiences and Future Strategies (2002), Wiley-VCH Verlag, Weinheim, Germany
14. Nadler R., Luo Y., Zhao W., Ritchey J.K., Austin J.C., Cohen M.B., et al. Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guerin (BCG) mediated antitumour activity. Clin Exp Immunol 131 (2003) 206
15. Nilsson S., Ragnhammar P., Glimelius B., Nygren P., and SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in urothelial bladder cancer. Acta Oncol 40 (2001) 371
16. Bartoletti R., Cai T., Dal Canto M., Boddi V., Nesi G., and Piazzini M. Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: a rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol 175 (2006) 2032
17. Hilmy M., Campbell R., Bartlett J.M., McNicol A.M., Underwood M.A., and McMillan D.C. The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer 95 (2006) 1234
18. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., and Marberger M. ImmunoCyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 161 (1999) 1486
19. Agarwal A., Verma S., Burra U., Murthy N.S., Mohanty N.K., and Saxena S. Flow cytometric analysis of Th1 and Th2 cytokines in PBMCs as a parameter of immunological dysfunction in patients of superficial transitional cell carcinoma of bladder. Cancer Immunol Immunother 55 (2006) 734
20. Suttmann H., Jacobsen M., Reiss K., Jocham D., Bohle A., and Brandau S. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation. J Urol 172 (2004) 1490